REPLIGEN CORP Amortization of Debt Issuance Costs
REPLIGEN CORP (RGEN) reported Amortization of Debt Issuance Costs of $421.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-07-29
- REPLIGEN CORP amortization of debt issuance costs for the quarter ending 2026-06-30 was $421.00K, a 1.69% increase year-over-year.
- REPLIGEN CORP amortization of debt issuance costs for the quarter ending 2026-03-31 was $419.00K, a 1.45% increase year-over-year.
- REPLIGEN CORP amortization of debt issuance costs for the quarter ending 2025-12-31 was $417.00K, a 1.46% increase year-over-year.
- REPLIGEN CORP amortization of debt issuance costs for the quarter ending 2025-09-30 was $416.00K, a 3.03% decline year-over-year.
- REPLIGEN CORP amortization of debt issuance costs for fiscal 2025 was $1.66M, a 9.93% decline from fiscal 2024.
- REPLIGEN CORP amortization of debt issuance costs for fiscal 2024 was $1.84M, a 77.18% decline from fiscal 2023.
- REPLIGEN CORP amortization of debt issuance costs for fiscal 2023 was $8.07M.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $421.00K 10-Q · filed 2026-07-29 | $840.00K 10-Q · filed 2026-07-29 | $1.26M derived: sum of 3 quarters · filed 2026-07-29 | $1.67M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $419.00K 10-Q · filed 2026-05-06 | $836.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.25M derived: sum of 3 quarters · filed 2026-05-06 | $1.67M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $417.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $833.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.25M derived: sum of 3 quarters · filed 2026-07-29 | $1.66M 10-K · filed 2026-02-26 |
| 2025-09-30 | $416.00K 10-Q · filed 2025-11-04 | $830.00K derived: sum of 2 quarters · filed 2026-07-29 | $1.24M 10-Q · filed 2025-11-04 | $1.65M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $414.00K 10-Q · filed 2026-07-29 | $827.00K 10-Q · filed 2026-07-29 | $1.24M derived: sum of 3 quarters · filed 2026-07-29 | $1.67M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $413.00K 10-Q · filed 2026-05-06 | $824.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.25M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $411.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $840.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.84M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $429.00K 10-Q · filed 2025-11-04 | $1.43M 10-Q · filed 2025-11-04 | ||
| 2023-12-31 | $6.70M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | $7.16M derived: sum of 2 quarters · filed 2026-02-26 | $7.62M derived: sum of 3 quarters · filed 2026-02-26 | $8.07M 10-K · filed 2026-02-26 |
| 2023-09-30 | $459.00K 10-Q · filed 2023-10-31 | $916.00K derived: sum of 2 quarters · filed 2023-10-31 | $1.37M 10-Q/A · filed 2024-11-18 | |
| 2023-06-30 | $457.00K 10-Q · filed 2023-08-02 | $914.00K 10-Q/A · filed 2024-11-18 | ||
| 2023-03-31 | $457.00K 10-Q/A · filed 2024-11-18 | |||
| 2022-09-30 | $455.00K 10-Q · filed 2023-10-31 | $908.00K derived: sum of 2 quarters · filed 2023-10-31 | $1.36M 10-Q/A · filed 2024-11-18 | |
| 2022-06-30 | $453.00K 10-Q · filed 2023-08-02 | $905.00K 10-Q/A · filed 2024-11-18 | ||
| 2022-03-31 | $452.00K 10-Q/A · filed 2024-11-18 | |||
| 2021-09-30 | $361.00K 10-Q · filed 2022-11-01 | $718.00K derived: sum of 2 quarters · filed 2022-11-01 | $1.07M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $357.00K 10-Q · filed 2022-08-02 | $709.00K 10-Q · filed 2022-08-02 | ||
| 2021-03-31 | $352.00K 10-Q · filed 2022-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |